α-TEA in Advanced Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

17

Participants

Timeline

Start Date

August 4, 2014

Primary Completion Date

December 11, 2017

Study Completion Date

May 8, 2018

Conditions
Metastatic CarcinomaMetastatic SarcomaMetastatic Lymphoma
Interventions
DRUG

2.4 mg/kg α-TEA

Patients receive oral α-TEA 2.4 mg/kg daily for the first 14 days of a 28 day cycle.

DRUG

4.8 mg/kg α-TEA

Patients will receive oral α-TEA 4.8 mg/kg daily for the first 14 days of a 28 day cycle.

DRUG

8.0 mg/kg α-TEA

Patients will receive oral α-TEA 8.0 mg/kg daily for the first 14 days of a 28 day cycle.

DRUG

9.6 mg/kg α-TEA

Patients will receive oral α-TEA 9.6 mg/kg daily for the first 14 days of a 28 day cycle.

DRUG

12 mg/kg α-TEA

Patients will receive oral α-TEA 12 mg/kg daily for the first 14 days of a 28 day cycle.

DRUG

16.8 mg/kg α-TEA

Patients will receive oral α-TEA 16.8 mg/kg daily for the first 14 days of a 28 day cycle.

DRUG

19.2 mg/kg α-TEA

Patients will receive oral α-TEA 19.2 mg/kg daily for the first 14 days of a 28 day cycle.

DRUG

22.3 mg/kg α-TEA

Patients will receive oral α-TEA 22.3 mg/kg daily for the first 14 days of a 28 day cycle.

DRUG

26.8 mg/kg α-TEA

Patients will receive oral α-TEA 26.8 mg/kg daily for the first 14 days of a 28 day cycle.

Trial Locations (5)

97015

Providence Oncology & Hematology Care Clinic- Southeast, Clackamas

97045

Providence Oncology & Hematology Care Clinic- Willamette Falls, Oregon City

97132

Providence Oncology & Hematoloty Care Clinic- Newberg, Newberg

97213

Providence Oncology & Hematology Care Clinic- Eastside, Portland

97225

Providence Oncology & Hematology Care Clinic- Westside, Portland

All Listed Sponsors
lead

Providence Health & Services

OTHER

NCT02192346 - α-TEA in Advanced Cancer | Biotech Hunter | Biotech Hunter